ArticleCureus2025
Targeting Angiogenesis and Visual Cycle in Age-Related Macular Degeneration: The Role of Stem Cells and Vinpocetine.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose The purpose of this study was to evaluate whether bone marrow stem cells (BMSCs), vinpocetine, or their combination can attenuate amyloid-β (Aβ)-induced alterations in angiogenesis and visual cycle gene expression in a cellular model of age-related macular degeneration (AMD). Methods Human retinal pigment epithelium (RPE) cells (ARPE-19) were exposed to Aβ 1-42 for 24h and divided into four groups: (i) co-culture with BMSCs, (ii) treated with vinpocetine, (iii) treated with BMSCs and vinpocetine, and (iv) untreated control. Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay. Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to evaluate the mRNA expression levels of angiogenesis-related genes, vascular endothelial growth factor (VEGF-A) and pigment epithelium-derived factor (PEDF), and RPE-associated visual cycle genes: lecithin retinol acyltransferase (LRAT), retinoid isomerohydrolase (RPE65), retinol dehydrogenase 5 (RDH5), retinol dehydrogenase 10 (RDH10), and retinaldehyde-binding protein 1 (RLPB1). Results Aβ1-42 significantly reduced ARPE-19 cell viability (p=0.002); all treatments significantly restored viability. Aβ1-42 upregulated VEGF-A expression, which was significantly downregulated by all treatments. Although Aβ1-42 slightly increased PEDF expression, all treatments significantly enhanced its upregulation, with the combination therapy showing the greatest effect (p=0.006, 0.010, and 0.002, respectively). Furthermore, Aβ 1-42 induced upregulation of most visual cycle genes was reversed by all treatments. Conclusion Aβ1-42 induces cytotoxicity, angiogenesis, and dysregulation of visual cycle genes in RPE cells in vitro. BMSCs, vinpocetine, and their combination attenuate these effects, supporting a potential role in AMD therapy pending further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.